Clinical trials: PET/CT
Prostate Cancer
Ga-68 PSMA PET/CT vs mpMRI in Cognitive Prostate Biopsy
Prostate cancer is the most common malignancy among elderly men. With the routine use of prostate-specific antigen (PSA) testing since the 1980s, the incidence of prostate cancer has significantly increased.
- Trial name
- PSMA-MRI BX (NCT07533344)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Colon Cancer, Lung Cancer
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Background: Fluciclatide is a small cyclic peptide containing the RGD tri-peptide, which preferentially binds with high affinity to alpha(v)beta(3) integrins, which are up-regulated in and may regulate angiogenesis.
- Conditions
- Colon Cancer, Lung Cancer, Cervical Cancer, Renal Cell Carcinoma
- Trial name
- NCT01176500
- Testing
- (18)Fluciclatide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis - Extension Study
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid…
- Trial name
- VIP-E (NCT01866592)
- Testing
- Adalimumab
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania
Ovarian Cancer
Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics
The purpose of this research study is to learn if differences seen in scans before surgery match differences seen when looking at tumor samples with pathology and genetic tests.
- Trial name
- NCT02144311
- Testing
- PET/CT Scan, MRI
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
Comparing FDG PET/CT and FDG PET/MRI in the diagnostic accuracy of detecting local recurrence 12 weeks after the end of CRT in head and neck squamous cell carcinoma patients.
- Trial name
- HENEPET (NCT04196985)
- Testing
- PET/MRI, PET/CT
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Turku University Hospital
Malignant Tumors
PET/CT-Guided Biological Target Volume Delineation and Dose Optimization for Radioactive Seed Implantation Therapy in Malignant Tumors
This prospective, open-label Phase I/II trial evaluates a PET/CT-guided planning strategy for radioactive seed implantation therapy in malignant solid tumors.
- Trial name
- NCT07327515
- Testing
- CT-Guided Radioactive Seed Implantation, PET/CT-Guided Radioactive Seed Implantation, PET/CT-Guided Radioactive Seed Implantation (Biological Dose Optimization)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min
Prostate Cancer
FACBC Outcomes for Post Prostatectomy
Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy.
- Trial name
- NCT01666808
- Testing
- FACBC, Radiation therapy
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Emory University
Mantle Cell Lymphoma
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
This is a single-arm, multi-center, prospective, phase II study. The primary objective is to assess the efficacy and safety of bendamustine/orelabrutinib combined with an anti-CD20 monoclonal antibody in treatment-naïve patients…
- Trial name
- ADAPT-MCL (NCT07206264)
- Testing
- Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ovarian Cancer
Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential toxic therapy in non…
- Trial name
- NCT00620243
- Testing
- 1: FDG PET
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
- Trial name
- LIFE (NCT06107608)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 58 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer
Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports
This observational study will develop and validate a large language model-assisted workflow for imaging cTNM staging annotation and uncertainty recognition in prostate cancer using Chinese PSMA PET/CT report texts generated…
- Trial name
- PSMA-LLM-cTNM (NCT07707232)
- Testing
- Large Language Model-Assisted Report Annotation
- Where
- China
- Volunteers
- 4,600 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Neurodegenerative Disease, Alzheimer s Disease
[18F]NIDF PET Imaging in Tau-related Diseases
In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body.
- Conditions
- Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
- Trial name
- NCT07306598
- Where
- 3 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Prostate Cancer, High Risk
68 Ga-PSMA for High Risk Prostate Cancer
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence.
- Trial name
- NCT04614363
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
Anal Cancer
Individual Following in Anal Cancer With PET/CT
Anal canal cancer is a relatively rare disease, representing 1.2% of digestive cancers and 6% of anorectal cancers. Incidence is less than 1/100 000 of the general population.
- Trial name
- IFACT (NCT02697084)
- Testing
- anal cancer
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Vulvar Cancer
Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy
The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines.
- Trial name
- GroSNaPET (NCT02969278)
- Testing
- 18FDG-PET/TC, Sentinel node biopsy
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Catholic University of the Sacred Heart
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine Neoplasms
68Ga-NYM215 in NENs
This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms.
- Trial name
- NCT07835906
- Testing
- 68Ga-NYM215 PET/CT, 68Ga-DOTATATE PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Healthy Volunteer, Coronary Arterial Disease
Ultralow Dose PET Imaging of 18F-flurpiridaz
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction)…
- Conditions
- Healthy Volunteer, Coronary Arterial Disease, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT07284576
- Testing
- 18F-flurpiridaz
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Diffuse Large B-cell Lymphoma
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL
This retrospective study aimed to investigate the combined prognostic values of intratumoral metabolic heterogeneity (MH), disseminate feature (Dmax) and total metabolic tumor volume (TMTV) by 2-deoxy-2-[18F]fluoro-D-glucose…
- Trial name
- NCT05113576
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.